CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25 enrolled
Drug / intervention
SGLT2 inhibitordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04342819
NCT04342819Phase 3Completed
CompareCT.gov

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

The University of The West Indies·interventional·Posted Apr 13, 2020·Updated Sep 3, 2024

In Brief

A Phase 3 clinical trial evaluating SGLT2 inhibitor for Platelet Dysfunction Due to Drugs. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The mechanistic effects of empagliflozin on platelet function profiles have not yet been ascertained.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatelet Dysfunction Due to Drugs
CountriesTrinidad and Tobago
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 13, 2020
Enrollment StartJan 1, 2020
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 6.2 years ago

Interventions

SGLT2 inhibitordrug

Sodium-Glucose Like Transporter 2 Inhibitor